Depression Screening Market Rising at 6.20% CAGR with Global Key Players: Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Johnson & Johnson Services, Inc. and Novartis AG

The Global Depression Screening Market is expected to grow at a CAGR of 6.20% during the forecast period 2017-2023. Depression and mental health are the leading cause of disability and ill health across the globe. Depression affects an estimated one in 15 adults every year and also affects one in six people will experience depression at some time in their life. Depression can strike at any age but on average it appears during the late teens to mid-20s.

Women are more likely than men to experience these depression related disorders. According to the latest estimations from (World Health Organization) WHO, more than 300 million people are now living having depression with an increase of more than 18% between 2005 and 2015. Depression is a kind of mental condition that causes individuals to experience depressed mood, loss of interest, feelings of low self-worth, disturbed sleep or appetite, low energy, and poor concentration. An individual who is suffering from depression experiences intense emotions of anxiety, hopelessness, negativity and helplessness.

Get Exclusive Sample Copy @ https://www.marketresearchfuture.com/sample_request/3806 .

​​​​​​​Depression Screening Market Key Players:

Some of the key players in this market are Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co.,Ltd. (Japan),  Pfizer Inc. (US) and others.

Depression Screening Market Segmentation

The global depression screening market is segmented on the basis of disease type, diagnosis, treatment, and end user.

On the basis of the disease type, it is further segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, eating disorders and other mental and behavioral & disorders.

On the basis of the diagnosis, the market is segmented into psychological test, Lab tests, depression screening tests and others.

On the basis of the treatment, the market is segmented into medication (anti-anxiety medications, antidepressants, antipsychotic medications, stimulants, anti-seizures medications and others), brain-stimulation treatments (Vagus Nerve Stimulation (VNS), repetitive Transcranial Magnetic Stimulation (rTMS), Magnetic Seizure Therapy (MST), and Deep Brain Stimulation (DBS)), substance abuse treatment and others.

On the basis of the end user, the market is segmented into hospitals and clinics, medical research centers, academic institutes, and others.

Depression Screening Market Regional Analysis

The Americas have the largest market share of the global depression screening market. This is largely owing to the up-to-date diagnostic and treatment options available. Research for mental health is well funded and due to awareness of mental health disorders, there is a demand for depression and mental health screening in this region, particularly in countries such as U.S and Canada.

Europe, with it's second largest market share, is expected to grow significantly during the forecast period. This is attributable to similar growth patterns as the Americas. Germany, France and the U.K are the top three markets in this region, they have a strong presence of major players which further influence growth.

Asia Pacific is projected to be the fastest growing market, globally. The presence of numerous emerging economies that are experiencing an increased prevalance of mental health disorders is predicted to drive growth. Increasing awareness of mental health disorders in this region combined with a rapidly advancing healthcare sector has set this region to grow exponentially during the forecast period.

Meanwhile, the Middle East and Africa region has the smallest global market share largely owing to the low availability of relevant medical facilities and an under developed healthcare sector. However, countries in the middle east with well-developing economies such as Qatar are expected to see some growth.

Browse Complete Report @ https://www.marketresearchfuture.com/reports/depression-screening-mental-health-market-3806 .

MAJOR TOC FOR DEPRESSION SCREENING MARKET RESEARCH REPORT - GLOBAL FORECAST TILL 2023:

1  REPORT PROLOGUE

2  MARKET INTRODUCTION

2.1 Scope Of Study

2.2 Research Objective

2.3 Assumptions & Limitations

2.3.1 Assumptions

2.3.2 Limitations

3  RESEARCH METHODOLOGY

3.1 Primary Research Methodology

3.2 Secondary Research Methodology

3.3 Market Share Analysis

3.4 Trade Analysis

3.5 Market Pricing Approach

4  MARKET DYNAMICS

4.1 Introduction

4.2 Drivers

4.2.1 Emergence Of Digital Health Technologies In Mental Health

(Impact Weightage-45%)

4.2.2 Growing Prevalence Of Mental Disorders Around The Globe

(Impact Weightage-30%)

4.2.3 New Focus Areas In The Care Continuum Are Prevention And Recovery

(Impact Weightage-25%)

4.3 Restraints

4.3.1 Low Public Awareness Of Mental Disorders And Treatments In Emerging Nations (Impact Weightage-55%)

TOC Continued…..!

Ask to Experts @ https://www.marketresearchfuture.com/enquiry/3806 .

About US:

Market Research Future (MRFR), enable customers to unravel the complexity of various industries through Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Raw Research Reports (3R), Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Office No. 528, Amanora Chambers

Magarpatta Road, Hadapsar,

Pune - 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.